Le Lézard
Classified in: Health, Science and technology
Subjects: MISCELLANEOUS, MISCELLANEOUS

ProMIS Neurosciences to Participate in Guggenheim's Inaugural Healthcare Innovation Conference


CAMBRIDGE, Massachusetts and TORONTO, Ontario, Nov. 12, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference on Wednesday, November 13, 2024 at 10:00 a.m. ET in Boston, MA.

A live webcast of the fireside chat may be accessed by visiting the Events page of the Company's website at www.promisneurosciences.com, and will be available for at least 30 days following the event.

About ProMIS Neurosciences Inc.

ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company's proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIStm and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. PMN310, the Company's lead product candidate for the treatment of AD, is a differentiated, humanized monoclonal antibody that has been designed to specifically bind toxic A? oligomers and to not bind plaque or monomers. Oligomers are known to drive disease progression in AD and PMN310 appears to be is the only antibody to selectively bind oligomers, which is expected to support better safety and efficacy. PMN 310 has successfully completed a Phase 1a clinical study and ProMIS expects to initiate a Phase 1b clinical trial in AD patients by year end 2024. ProMIS has offices in Cambridge, Massachusetts and Toronto, Ontario.

For further information:

Visit us at www.promisneurosciences.com.

Please submit media inquiries to [email protected].

For Investor Relations, please contact:
Precision AQ (formerly Stern IR)
Anne Marie Fields, Managing Director
[email protected]
Tel. 212-362-1200



These press releases may also interest you

at 10:40
Pharmascience Canada is proud to announce the launch of  Pr pms-RUPATADINE (rupatadine), a treatment that helps relieve nasal and non-nasal symptoms of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR), as well as symptoms...

at 10:32
AI is the new trend in the market, making a significant impact across various sectors. It's not just a buzzword; AI is revolutionizing how industries operate. By boosting efficiency, speeding up discoveries, and ultimately saving lives, AI is proving...

at 10:30
The cochlear implants market valued at US$ 2.58 Billion in 2023, is forecasted to grow at a robust CAGR of 9.2%, reaching US$ 2.80 Billion in 2024 and an impressive US$ 4.73 Billion by 2030. The cochlear implants market is driven by factors such as...

at 10:21
My Green Mattress, a leading family-owned manufacturer of certified organic mattresses, announces its Presidents Day Sale, offering a significant 15% discount on certified organic mattresses and sleep accessories. From February 7th to 25th, 2025,...

at 10:05
eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the successful transplantation of a genetically engineered porcine kidney into a second patient living with...

at 10:00
LifeNet Health's Organ Procurement Organization (OPO) is proud to mark another milestone in its mission to save and improve lives. In 2024, LifeNet Health achieved its seventh record-breaking year in the past eight years with 299 donors providing 857...



News published on and distributed by: